BirchBioMed – Anti-scarring | Auto-immune Therapeutics | Transplantation

Building the Future of Therapeutic Healing of Fibrosis and Autoimmune Disorders

BirchBioMed is a pioneering clinical-stage biopharmaceutical company focused on developing innovative treatments for diseases with high unmet medical needs like organ fibrosis, scarring, skin disorders, and specific clinical autoimmune conditions like Type 1 Diabetes (T1D). Leveraging groundbreaking technologies licensed from the University of British Columbia, BirchBioMed is committed to transforming patient care. Our advanced therapies are poised to set new standards in medical treatment, pending regulatory approvals. With a mission to save lives and cure severe diseases, BirchBioMed is dedicated to delivering transformative healthcare solutions globally.

Novel Technology Platforms Addressing Multiple Therapeutic Indications

BirchBioMed is revolutionizing the treatment landscape for fibrosis and certain autoimmune disorders through its advanced scientific innovations. Centered around the potent antifibrogenic properties of Kynurenic Acid (KynA), our treatments span from topical applications to systemic therapies, addressing critical healthcare challenges. KynA not only enhances extracellular matrix remodeling but also effectively reduces uncontrolled fibroblast proliferation and tissue cellularity, crucial for managing excessive scarring and organ fibrosis. In addition, our unique combination of KynA with antigen-presenting cells (APCs) offers a novel, promising and synergistic approach to the treatment of specific autoimmune disorders. Our therapies are not just treatments but potential cures, aiming to transform patient outcomes in diseases ranging from idiopathic pulmonary fibrosis to T1D and beyond. Through rigorous clinical trials and strategic global outreach, BirchBioMed is poised to deliver transformative solutions that promise a new era of healthcare.

Pioneering Groundbreaking Treatments for Fibrosis and Autoimmune Disorders

BirchBioMed is dedicated to addressing some of the most urgent and challenging health conditions, including organ fibrosis, specific autoimmune disorders, and skin-related ailments. Each year, over 100 million patients in the developed world suffer from scarring following surgeries and traumas, often leading to severe physical and psychological impacts. Organ fibrosis, a critical concern linked to chronic diseases such as liver cirrhosis and idiopathic pulmonary fibrosis, contribute to nearly 45% of all deaths in the developed world, underscoring the acute need for innovative treatments. Birch BioMed is targeting certain, specific autoimmune conditions by addressing the immune system’s complex misdirected attacks on healthy tissues. Moreover, as the global market for anti-aging products soars, BirchBioMed is at the forefront, developing effective treatments that address both intrinsic aging factors such as wrinkles and rhytids and environmental impacts that result in life-threatening fibrosis. BirchBioMed's commitment to pioneering advanced therapeutic strategies offers new hope for improving patient outcomes across a spectrum of life-altering conditions.

Robust Portfolio of Innovative Treatments

BirchBioMed is advancing a compelling portfolio of therapies in mid-to-late stage clinical trials, targeting fibrosis and specific autoimmune disorders. Our innovations include KynA in topical creams for dermatological conditions, systemic administration for organ fibrosis, and in a novel combination with APCs for subsets of autoimmune disorders like T1D and Alopecia Areata (AA). Each therapy is under rigorous evaluation across eight distinct programs, promising transformative treatments with the potential to significantly improve patient outcomes and cure diseases globally.

Our Products & Pipeline

Building the Future of Therapeutic Healing of Fibrosis and Autoimmune Disorders

BirchBioMed is a pioneering clinical-stage biopharmaceutical company focused on developing innovative treatments for diseases with high unmet medical needs like organ fibrosis, scarring, skin disorders, and specific clinical autoimmune conditions like Type 1 Diabetes (T1D). Leveraging groundbreaking technologies licensed from the University of British Columbia, BirchBioMed is committed to transforming patient care. Our advanced therapies are poised to set new standards in medical treatment, pending regulatory approvals. With a mission to save lives and cure severe diseases, BirchBioMed is dedicated to delivering transformative healthcare solutions globally.

Novel Technology Platforms Addressing Multiple Therapeutic Indications

BirchBioMed is revolutionizing the treatment landscape for fibrosis and certain autoimmune disorders through its advanced scientific innovations. Centered around the potent antifibrogenic properties of Kynurenic Acid (KynA), our treatments span from topical applications to systemic therapies, addressing critical healthcare challenges. KynA not only enhances extracellular matrix remodeling but also effectively reduces uncontrolled fibroblast proliferation and tissue cellularity, crucial for managing excessive scarring and organ fibrosis. In addition, our unique combination of KynA with antigen-presenting cells (APCs) offers a novel, promising and synergistic approach to the treatment of specific autoimmune disorders. Our therapies are not just treatments but potential cures, aiming to transform patient outcomes in diseases ranging from idiopathic pulmonary fibrosis to T1D and beyond. Through rigorous clinical trials and strategic global outreach, BirchBioMed is poised to deliver transformative solutions that promise a new era of healthcare.

Pioneering Groundbreaking Treatments for Fibrosis and Autoimmune Disorders

BirchBioMed is dedicated to addressing some of the most urgent and challenging health conditions, including organ fibrosis, specific autoimmune disorders, and skin-related ailments. Each year, over 100 million patients in the developed world suffer from scarring following surgeries and traumas, often leading to severe physical and psychological impacts. Organ fibrosis, a critical concern linked to chronic diseases such as liver cirrhosis and idiopathic pulmonary fibrosis, contribute to nearly 45% of all deaths in the developed world, underscoring the acute need for innovative treatments. Birch BioMed is targeting certain, specific autoimmune conditions by addressing the immune system’s complex misdirected attacks on healthy tissues. Moreover, as the global market for anti-aging products soars, BirchBioMed is at the forefront, developing effective treatments that address both intrinsic aging factors such as wrinkles and rhytids and environmental impacts that result in life-threatening fibrosis. BirchBioMed's commitment to pioneering advanced therapeutic strategies offers new hope for improving patient outcomes across a spectrum of life-altering conditions.

Robust Portfolio of Innovative Treatments

BirchBioMed is advancing a compelling portfolio of therapies in mid-to-late stage clinical trials, targeting fibrosis and specific autoimmune disorders. Our innovations include KynA in topical creams for dermatological conditions, systemic administration for organ fibrosis, and in a novel combination with APCs for subsets of autoimmune disorders like T1D and Alopecia Areata (AA). Each therapy is under rigorous evaluation across eight distinct programs, promising transformative treatments with the potential to significantly improve patient outcomes and cure diseases globally.

Our Products & Pipeline

BirchBioMed

Millions suffer with few available treatments for their debilitating medical issues.

BirchBioMed is a global, cutting-edge clinical-stage biopharmaceutical company headquartered in Canada. The company is dedicated to pioneering innovative treatments for organ fibrosis, scarring (fibrosis) and associated skin disorders, as well as specific autoimmune disorders, including Type 1 Diabetes (T1D) and Alopecia Areata (AA).

our focus

Develop life-changing treatments to solve unmet medical needs.

BirchBioMed leads the way in biopharmaceuticals, developing advanced treatments for fibrosis and subsets of specific autoimmune disorders. Our focus is on Kynurenic Acid (KynA), a compound with antifibrogenic properties, used in topical, systemic, and cutting-edge therapies to reshape fibrosis treatments and, in combination with antigen-presenting cell (APC) therapy, to address certain autoimmune disorders.

Explore our groundbreaking approach to improving patient outcomes.

The Team

A deeply experienced team
of healthcare leaders.

At BirchBioMed, our team of world-class scientists, researchers, and business professionals drives the development of groundbreaking therapies. Together, we are shaping the future of healthcare with passion and precision. Get to know the experts behind our success.

Partnering

Empower our mission to help millions.

At BirchBioMed, we believe in the power of collaboration to advance medical innovation and enhance patient care. Our strategic partnering opportunities are designed to forge alliances that leverage our cutting-edge research and development in the field of biopharmaceuticals.

investors

Invest in the Future of Healthcare Innovation

Prepared to be publicly listed in a few months, we are positioned to potentially transform the future of healthcare in major therapeutic indications. With a Total Addressable Market (TAM) of $96.9B, our innovative therapies target high-impact diseases, offering significant growth potential for investors.